Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).

被引：0
|
作者：
Tam, Eric Leon
Iberri, David Joseph
Liedtke, Michaela
Muffly, Lori S.
Shiraz, Parveen
Frank, Matthew Joshua
Lowsky, Robert
Rezvani, Andrew
Negrin, Robert
Meyer, Everett
Arai, Sally
Johnston, Laura J.
Shizuru, Judith
Weng, Wen-Kai
Miklos, David Bernard
Sidana, Surbhi
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Stanford, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20557
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A Retrospective Study of Serum Indicators in Functional High-Risk Multiple Myeloma Patients Undertaking Proteasome Inhibitors Treatments
    Zhan, Linquan
    Yuan, Dai
    Ge, Xueling
    Ding, Mei
    Zhou, Xiangxiang
    Wang, Xin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S251 - S251
  • [32] KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma
    Gaballa, Mahmoud R.
    Ma, Junsheng
    Rauf, Mikael
    Bassett, Roland
    Pasvolsky, Oren
    Tanner, Mark R.
    Bashir, Qaiser
    Srour, Samer A.
    Saini, Neeraj
    Ramdial, Jeremy
    Nieto, Yago
    Murphy, Regan
    Rezvani, Katayoun
    Tang, Guilin
    Lin, Pei
    Lee, Hans C.
    Patel, Krina K.
    Ullah, Muhammad R.
    Kaufman, Gregory P.
    Manasanch, Elisabet E.
    Kebriaei, Partow
    Thomas, Sheeba K.
    Weber, Donna M.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Orlowski, Robert Z.
    Qazilbash, Muzaffar H.
    BONE MARROW TRANSPLANTATION, 2022, 57 (07) : 1142 - 1149
  • [33] KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma
    Mahmoud R. Gaballa
    Junsheng Ma
    Mikael Rauf
    Roland Bassett
    Oren Pasvolsky
    Mark R. Tanner
    Qaiser Bashir
    Samer A. Srour
    Neeraj Saini
    Jeremy Ramdial
    Yago Nieto
    Regan Murphy
    Katayoun Rezvani
    Guilin Tang
    Pei Lin
    Hans C. Lee
    Krina K. Patel
    Muhammad R. Ullah
    Gregory P. Kaufman
    Elisabet E. Manasanch
    Partow Kebriaei
    Sheeba K. Thomas
    Donna M. Weber
    Elizabeth J. Shpall
    Richard E. Champlin
    Robert Z. Orlowski
    Muzaffar H. Qazilbash
    Bone Marrow Transplantation, 2022, 57 : 1142 - 1149
  • [34] Racial Differences in High-Risk Cytogenetic Mutations and Outcomes in Multiple Myeloma
    Derman, Ben A.
    Chernoff, Meytal
    Jakubowiak, Andrzej
    Chiu, Brian C. -H.
    BLOOD, 2019, 134
  • [35] Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy
    Mateos, Maria-Victoria
    Szarejko, Monika
    Bila, Jelena
    Schjesvold, Fredrik
    Spicka, Ivan
    Maisnar, Vladimir
    Jurczyszyn, Artur
    Grudeva-Popova, Zhanet
    Hajek, Roman
    Usenko, Hanna
    Thuresson, Marcus
    Norin, Stefan
    Jarefors, Sara
    Richardson, Paul
    Pour, Ludek
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S200 - S201
  • [36] Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma
    Zanwar, Saurabh
    Ho, Matthew
    Kapoor, Prashant
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Dingli, David
    Kourelis, Taxiarchis
    Fonder, Amie
    Hobbs, Miriam
    Hwa, Yi
    Gonsalves, Wilson
    Warsame, Rahma
    Muchtar, Eli
    Leung, Nelson
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji
    LEUKEMIA, 2022, 36 (03) : 873 - 876
  • [37] Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma
    Saurabh Zanwar
    Matthew Ho
    Prashant Kapoor
    Angela Dispenzieri
    Martha Q. Lacy
    Morie A. Gertz
    Francis K. Buadi
    Suzanne R. Hayman
    David Dingli
    Taxiarchis Kourelis
    Amie Fonder
    Miriam Hobbs
    Yi Hwa
    Wilson Gonsalves
    Rahma Warsame
    Eli Muchtar
    Nelson Leung
    Robert A. Kyle
    S. Vincent Rajkumar
    Shaji Kumar
    Leukemia, 2022, 36 : 873 - 876
  • [38] Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma
    Zanwar, Saurabh
    Ho, Matthew
    Kapoor, Prashant
    Dispenzieri, Angela
    Gertz, Morie A.
    Lacy, Martha Q.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Dingli, David
    Kourelis, Taxiarchis
    Fonder, Amie
    Hwa, Yi L.
    Hobbs, Miriam A.
    Gonsalves, Wilson I.
    Warsame, Rahma M.
    Muchtar, Eli
    Leung, Nelson
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji
    BLOOD, 2021, 138
  • [39] Treatment options for multiple myeloma patients with high-risk disease
    Ailawadhi, Sikander
    Masood, Aisha
    Sher, Taimur
    Miller, Kena C.
    Wood, Margaret
    Lee, Kelvin
    Chanan-Khan, Asher
    MEDICAL ONCOLOGY, 2010, 27 : 53 - 61
  • [40] Genomic characterization of functional high-risk multiple myeloma patients
    Soekojo, Cinnie Yentia
    Chung, Tae-Hoon
    Furqan, Muhammad Shaheryar
    Chng, Wee Joo
    BLOOD CANCER JOURNAL, 2022, 12 (01)
12345